Clinical Trials Logo
NCT number NCT03351140
Study type Observational
Source GlaxoSmithKline
Contact US GSK Clinical Trials Call Center
Phone 877-379-3718
Status Recruiting
Phase N/A
Start date December 20, 2017
Completion date April 30, 2018

Clinical Trial Summary

The objective of this study is to conduct in-person qualitative interviews of subjects who have different tumor types to identify and assess relevant PROMIS physical function items that can be utilized in future studies. Health Research Associates (HRA) will conduct qualitative interviews in subjects with a variety of cancer types. PROMIS is a set of self‐report measurement tools, developed by the United States (US) National Institutes for Health (NIH). The most recent version of PROMIS Physical Function Item Bank contains 165 items assessing a range of abilities and its subset, a 45-item PROMIS Function Cancer Item Bank which contains questions relevant to subjects with cancer. Approximately 150 subjects with five tumor types will be recruited. HRA will conduct the interviews that will be audio-recorded for transcription and analysis. Five tumor types that will be focused on are Breast, Prostate, Non‐Small‐Cell Lung Cancer (NSCLC), Multiple Myeloma, and Diffuse Large B‐Cell (DLBCL) or Follicular Lymphoma. Interviews will be conducted in English language in private areas within clinic site or rented meeting facilities and will last approximately for 60-90 minutes.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

See also
  Status Clinical Trial Phase
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Active, not recruiting NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development N/A
Recruiting NCT03167372 - Pilot N-of-1 Light Therapy Study N/A
Recruiting NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Completed NCT01077414 - Phenomenological Study of Psycho-Socio-Spiritual Healing in the Context of Chronic or Life-Threatening Illness N/A
Enrolling by invitation NCT02565004 - Clinical and Laboratory Analysis of Familial Cancer N/A
Completed NCT01340846 - A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors Phase 1
Active, not recruiting NCT02502396 - Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center N/A
Recruiting NCT03247309 - TCR-engineered T Cells in NSCLC and HNSCC Patients (ACTengine) Phase 1
Active, not recruiting NCT00587886 - Estrogen, Diet, Genetics and Endometrial Cancer N/A
Active, not recruiting NCT00984035 - Investigation of Cisplatin-Related Kidney Toxicity N/A
Not yet recruiting NCT03257969 - Impact of the DROP Program on the DRP (Drug Related Problems) Related to Oral Anticancer Drugs in Ambulatory Patients With Risk Factors N/A
Recruiting NCT02883699 - Individually Tailored Training Prescriptions in Cancer Patients: The TOP Study N/A
Recruiting NCT02869802 - Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis N/A
Recruiting NCT02839889 - Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation) Phase 4
Active, not recruiting NCT02891993 - Pilot Study of a Symptom Monitoring Intervention for Hospitalized Patients With Cancer N/A
Recruiting NCT02550925 - Acceptance and Commitment Therapy (ACT) for Anxious Cancer Survivors N/A
Recruiting NCT02552953 - A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers Phase 1